Angarus Therapeutics
Sunnyvale
About Angarus Therapeutics
Angarus Therapeutics develops immuno-oncology therapies intended to respond to the urgent needs of cancer treatment. The therapy serves as checkpoint blockers on the innate immunity STING pathway, with preclinical data demonstrating that a combination of checkpoint blockers, both innate and adaptive, leads to long term survival, enabling patients with a wide range of cancer treatments. Chih-Ping Liu established the company in Sunnyvale, California in 2018.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Total funding: $11.3M
- Last round: Series Unknown (Dec 2020)
- Website: angarustherapeutics.com
- Phone: 650-575-1702
Industries & Categories
Biotechnology, Health Care, Oncology, Therapeutics
Canonical: https://fsome.com/organization/angarus-therapeutics-115332 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.